Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Heron Therapeutics (HRTX) EBITDA Margin (2016 - 2025)

Heron Therapeutics (HRTX) has disclosed EBITDA Margin for 12 consecutive years, with 7.27% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA Margin fell 1618.0% year-over-year to 7.27%, compared with a TTM value of 13.04% through Dec 2025, down 363.0%, and an annual FY2025 reading of 13.04%, down 363.0% over the prior year.
  • EBITDA Margin was 7.27% for Q4 2025 at Heron Therapeutics, up from 45.78% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 8.92% in Q4 2024 and bottomed at 272.37% in Q1 2022.
  • Average EBITDA Margin over 5 years is 108.68%, with a median of 72.79% recorded in 2022.
  • The sharpest move saw EBITDA Margin plummeted -6290bps in 2021, then surged 19853bps in 2022.
  • Year by year, EBITDA Margin stood at 264.58% in 2021, then surged by 75bps to 66.04% in 2022, then skyrocketed by 53bps to 31.29% in 2023, then surged by 128bps to 8.92% in 2024, then crashed by -182bps to 7.27% in 2025.
  • Business Quant data shows EBITDA Margin for HRTX at 7.27% in Q4 2025, 45.78% in Q3 2025, and 6.41% in Q2 2025.